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By the time she diagnosed with GM1 Gangliosidoses she is no 
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Beta-galactosidase-1 deficiency is rare lysosomal storage disorder which is also called as 
GLB1 deficiency or Landing disease. It is an autosomal recessive disorder whose age of 
onset is usually child hood.  Deficiency of beta – galatosidase enzyme due to mutations of 
GLB1 gene results in toxic accumulation of gangliosides in either body tissues or particularly 
in the central nervous system which ultimately ends up in neurovisceral, ophthalmological 
and dysmorphic features. The types of GM1 gangliosidosis is based on the age of onset; 
infantile form which is severe and rapidly progressive, a late infantile or juvenile form with 
onset usually from seventh month to 3 years of age accompanied with delayed motor and 
cognitive development and thirdly an adult or chronic form with late onset characterized by 
generalized dystonia. The severity of disease depends on the level of beta – galactosidase 
activity. Due to the wide spectrum of disease, the diagnosis may be difficult. Facial 
coarsening, hypertrophic gums, cherry -red macula, visceromegaly, dysostosis and 
psychomotor are some signs of storage disorders which may help to diagnose GM1 
gangliosidosis. The confirmative diagnosis is biochemical assay of beta – galactosidase 
activity by molecular genetic testing. GLB1 molecular analysis can be done either by 
chorionic villus or amniotic cells as prenatal diagnosis. There is no specific treatment for 
GM1 gangliosidosis; treatment is symptomatic as well as supportive. Extremely poor 
prognosis found in severe infantile form.  
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INTRODUCTION 
GM1 gangliosidosis is broadly classified 
under lysosomal storage disorder. It is an 
inherited autosomal recessive disorder that 
gradually degenerates nerve cells 
(neurons) in the brain and spinal cord 
[1,2]. Absence or significantly reduced 
level of vital enzyme called beta – 
galactosidase cause GM1 gangliosidosis 
[3,4]. Each child has 25% of having the 
disease if both the parents are carriers. In 
general population, the carrier rate is 
1/250.  Natives of French Canadians, 
Louisiana Cajuns and Ashkenazi Jews 
(1/27) have an increased risk with a carrier 
state compared to Irish/ British Isle (1/50 
to 1/150) [5]. Lysosomal storage disorders 
include nearly 50 different diseases with a 
combined incidence of 1:1500 to 1:7000 
births. Prevalence of GM1 among Maltese 
Islands is 1:3,700, Roma ancestry is 
1:10,000, and from Brazil is 1:17,000 [6]. 
Studies have proved that siblings are prone 
to get GM1 Gangliosidosis. For instance, 
Gascon et al. (1992) reported that two 
Saudi Arab siblings (brother and sisters of 
9 and 7 years respectively) were diagnosed 
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with developmental arrest, gait disturbance 
and dementia. In addition, both were 
confined to bed by 2 years of age, had 
progressive myoclonic epilepsy syndrome 
with hyperacusis and in due course, they 
had spastic quadriparesis which led to a 
decerebrate state. The CT scans revealed 
global brain atrophy and the deficiency of 
ß-galactosidase activity was confirmed by 
bone marrow biopsies. They had another 
sibling with same complaints but passed 
away at the age of three [7].  
 
Based on the onset or the first appearance 
of the clinical manifestation, GM1 
gangliosidoses are classified as type 1 - 
early or classic infantile, type 2 - late 
infantile or juvenile or type 3 - adult or 
chronic [8]. The child with type 1 or early 
infantile usually doesn’t survive beyond 
infanthood [2,9]. Neurodegeneration, 
convulsions, exaggerated startle response, 
early psychomotor deterioration such as 
decreased activity, lethargy in the first 
weeks like initial hypotonia (hypotonic 
infant with regression in milestones and 
hepatomegaly occur not only in 
gangliosidoses (i.e., GM1 type I, Tay-
Sachs, Sandhoff, fucosidosis, α-
mannosidosis) but also in mucolipidoses 
(i.e., sialidosis, I-cell disease, multiple 
sulfatase deficiency), 
mucopolysaccharidoses (i.e., Hurler 
syndrome), and glycogen storage 
disorders (i.e., Pompe disease)[10,11], 
followed by spasticity, delayed milestones, 
feeding problems, visual failure by 6 
months, secondary microcephaly, 
decerebrate rigidity by 1 year are 
neurological signs of GM1 gangliosidosis. 
In addition, skeletal abnormalities, 
particularly, joint stiffness, flexion 
contractures by 3 months, early 
subperiosteal bone formation, diaphyseal 
widening later, demineralization, 
thoracolumbar vertebral hypoplasia 
leading to fracture around age 3–6 months; 
kyphoscoliosis, dysostosis multiplex are 
some of the initial stage clinical 
manifestations. Also, gastro intestinal 
disorders like hepatosplenomegaly at 
around 6 months, distended abdomen; 
muscle weakness; macular cherry red spots 
in the eye by 6- 10 months or corneal 
opacities and deaf and blind by age 1 and 
hyperacusis (increased sensitivity to 
certain frequency) may be present in child. 
Over and above facial dysmorphology, 
frontal bossing, wide nasal bridge, facial 
edema or puffy eyelids, peripheral edema, 
epicanthus, long upper lip, 
microretrognathia, gingival hypertrophy 
(thick alveolar ridges), macroglossia, 
developmental regression (losing acquired 
skills) and profound intellectual disability 
are also seen. The child may die due to 
cardiac complication or pneumonia/ 
respiratory failure [12].  
 
Type 2 involves intermediate form of 
condition and hence, includes late infantile 
(around 18 months) or juvenile forms (3 - 
5 years) [12]. Usually these children have 
normal development initially, later develop 
developmental regression, distinctive 
facial features, or enlarged organs. Even 
though type 2 progresses are slower than 
type 1, but still it causes a shortened life 
expectancy. Type 3 is adult or chronic 
form as the onset is between 3 and 30 
years and represents the mildest end of the 
disease. Furthermore, muscle atrophy 
leading to dystonia (involuntary tensing of 
various muscles), abnormalities of the 
spinal cord, corneal clouding and 
angiokeratomas are also found.  
 
Acid β -galactosidase genotyping 
(molecular diagnosis of the beta – 1 
galactosidase gene - GLB1) to detect 
heterozygous carriers and affected patients 
[13,14], lumbar puncture to rule out 
GM1 ganglioside levels  which may be 
increased in CSF, skin biopsy to establish 
acid β -galactosidase activity in cultured 
fibroblasts, prenatal diagnosis such as 
amniocentesis or chorionic villi testing to 
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amniocytes or amniotic chorionic villi,  the 
screening test includes acid β -
galactosidase activity in peripheral blood 
leukocytes, not opted for the screening of 
heterozygote carriers as an overlap is often 
present between homozygotes without 
GM1 gangliosidosis and heterozygote 
carriers, an ancillary diagnostic test for 
galactose-containing oligosaccharides in 
urine, Complete Blood Count for 
Vacuolation of lymphocytes (nonspecific 
indicator in lysosomal storage disorders) 
and dried blood spots from new born 
screening filter paper (even after 15 
months in storage enable to diagnose)[15]. 
Skeletal radiographs may reveal dysostosis 
multiplex including thickened calvaria, J-
shaped enlarged sella turcica, wide 
spatula-shaped ribs, flared ilia, acetabular 
dysplasia and flat femoral heads, wide 
wedge-shaped metacarpals, shortened long 
bones with diaphyseal widening, and 
hypoplastic and anteriorly beaked 
thoracolumbar vertebrae. Delayed bone 
age also may be demonstrated. In the adult 
form, only mild vertebral changes may be 
observed [14]. Neuroimaging by CT scan 
or MRI generally reveals diffuse atrophy 
and white matter demyelination with or 
without basal ganglia changes. Bilateral 
T2-weighted hyperintensities in the 
putamen are a frequently reported MRI 
finding in adult-onset disease. Mild 
cerebral atrophy may also be observed in 
the adult form. MR spectroscopy has 
demonstrated increased striatal 
myoinositol. An ultrasound of the 
abdomen may demonstrate organomegaly, 
signs of cardiomyopathy or valvulopathy 
may be observed by echocardiography or 
electrocardiography and generalized 
dysrhythmia and epileptogenic foci 
electroencephalography. Bone marrow 
aspiration not recommended as diagnostic 
test since of nonspecific large foam cells, 
Gaucher cells, and ballooned cells have 
been reported in bone marrow but are 
typically reported in lower concentrations 
than in other lysosomal storage disorders 
[14]. Presence of Galactosyl-
oligosaccharides in amniotic fluid with 
high-performance liquid chromatography 
(HPLC) at 14 weeks gestation may help to 
diagnose GM1 gangliosidosis prenatally 
[16].  
 
CASE PRESENTATION  
This is 27 years old female with obstetric 
Score G1P0L0A0 presented with meconium 
stained liquor and delivered a single live 
term female baby with APGAR 7 and 9 at 
1 and 5 minutes by Caesarean Section.  
Both couples had family history of infant 
death with unidentified cause.  Although 
she had history of mild anaemia since 
childhood, she was diagnosed to have 
minor thalassemia.  
 
MANAGEMENT AND OUTCOMES 
Currently, there is no particular 
management for GM1 gangliosidosis. 
Although symptomatic treatment could 
help to reduce neurologic signs and 
symptoms but then does not significantly 
alter the progression of the condition. 
Mostly, the principle of treatment includes 
restoring the missing enzyme or 
decreasing the waste accumulation [1].  
Within 24 hours of the birth, the child had 
generalized convulsions and was referred 
to NICU. After blood investigations, the 
child was diagnosed with imbalanced 
electrolytes, particularly potassium and 
calcium within few hours of birth. 
Generalized convulsions were relieved by 
calcium gluconate whereas hypoxia by 
oxygen administration via nasal prongs, 
bilevel positive airway pressure (BiPAP) 
and oxygen concentrator later in life. 
Symptomatic (anticonvulsants for 
seizures) and supportive therapy like 
proper nutrition, hydration, maintaining 
clear airway, etc. was provided with care 
[17]. Physical examination discovered 
facial and peripheral edema, 
kyphoscoliosis, gingival hypertrophy and 
angiokeratomas (red to blue colour benign 
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abdomen and upper extremities since birth. 
She was diagnosed with delayed 
myelination with unmyelination deep 
white matter of corona radiata and centrum 
semiovale as expected for this age; wide 
spaced frontal horn of bilateral ventricles 
and mild colpocephaly by MRI at 5 
months. At 6 months, the leukocyte 
enzyme activity which is measured by beta 
galactosidase (nmol/h/mg) was highly 
diminished (1.2) in comparison to the 
normal range (70-324). USG stated hepato 
splenomegaly while visual evoked 
potential test revealed sign of visual 
pathway dysfunction at 7
th
 month. 
Piracetam is a gamma amnio butyric acid 
(GABA) analogues (protect brain against 
shortness of oxygen) was the major 
treatment. Neither bone marrow 
transplantation (though reported successful 
in infantile/juvenile for short- term benefit) 
nor pre-symptomatic cord- blood 
hematopoietic stem-cell transplantation 
(recommended due to its success in other 
lysosomal storage disorders) was not done. 
Occupational and Physiotherapy found to 
be beneficial. The child had feeding 
difficulty and was started on tube feeding. 
She developed abdominal distention, 
severe chest congestion and ended up with 





Nursing management  
Adequate information, support and 
counselling were made available for parent 
to make a future decision which indeed is 
essential.  Infant was laid on comfortable 
position and position was changed every 
two hourly as the baby could not move by 
her own. The child with infantile type may 
have feeding problems which could be 
overcome by tube feeding with adequate 
nutrients. Proper neck support, either by 
neck collar or towel, could prevent the 
complications of atlantoaxial instability. 
Steam inhalation and nebulization 
followed by chest physiotherapy was 
beneficial during chest congestion. A 
nurse plays a vital role in educating 
families of patients with GM1 
gangliosidosis. Planned adequate physical 
activity by occupational or physiotherapy 
could reduce skeletal difficulties.  
 
DISCUSSION  
GM1 gangliosidoses is an inherited 
autosomal recessive disorder with 
prevalence at birth is approximately 
1:100,000 to 200,000 live births across the 
globe [18]. It is due to the marked 
deficiency of beta – galactosidase resulting 
in abnormal acidic lipid materials in the 
nerve cells. Generally, GLB1 
(galactosidase beta -1) gene help to make a 
vital enzyme called beta – galactosidase 
and resides in cell compartments (called 
lysosomes) in order to metabolize certain 
molecules like GM1 ganglioside which is 
important for nerve cell function. Any 
mutation in GLB1 gene may decrease or 
eliminate the β -galactosidase enzyme. 
Consequently, it accumulates to toxic 
levels in tissues and organs, particularly in 
brain. Therefore, a fatty substance or lipid 
(called GM-1 ganglioside) accumulates 
abnormally in the nerve cells. Hence, this 
accumulation (called substrate) leads to 
progressive destruction of nerve cells [3].  
 
A study was conducted between 2011 and 
2014 among patients referred from all over 
India and Pakistan. The coarse facies, 
short stature, multiplex dysostosis (bone 
development disorder, particularly 
ossification), corneal clouding and 
hepatosplenomegaly were the most 
common phenotype considered for 
referred case. The study reported that 4 
were diagnosed with GM1 gangliosidosis 
by biochemically as well as confirmed by 
DNA analysis [19]. As India is a 
developing country, several cases could be 
unobserved due to difficulty in 
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CONCLUSION  
The untreated GM1 gangliosidosis result 
in devastating consequences on 
neurological system and eventually result 
in aspiration pneumonia, recurrent 
respiratory infections subsequent to 
neurologic compromise, congestive heart 
failure due to secondary cardiomyopathy 
(weakening of heart muscle) resulting in 
heart failure and atlantoaxial instability 
(AAI), i.e, characterized by excessive 
movement at the junction between atlas 
(C1) and axis (C2) leading to abnormally 
shaped cervical vertebrae. To conclude, 
genetic screening must be considered as 
priority suggestion for common public 
before conception in order to reduce grief 
and bereavement.  
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